8-KOther Events

BIOGEN INC. 8-K Report (Oct 14, 2003)

Filed October 14, 2003For Securities:BIIB

Summary

This Form 8-K filing from IDEC Pharmaceuticals Corporation, dated October 14, 2003, primarily serves to disclose their financial results for the third quarter ended September 30, 2003, via an attached press release (Exhibit 99.1). This report is crucial for investors as it provides a snapshot of the company's financial performance during the period, offering insights into revenue, profitability, and potentially other key financial metrics. Investors should review the press release for detailed information on operating results, financial condition, and any forward-looking statements or guidance provided by management. The filing adheres to Regulation FD disclosure requirements, ensuring that material information is broadly disseminated. While the 8-K itself is brief, its core value lies in the accompanying press release, which is the primary source of the financial and operational data investors will be looking for. Understanding these results is vital for assessing the company's current health and future prospects.

Key Highlights

  • 1IDEC Pharmaceuticals Corporation filed a Form 8-K on October 14, 2003.
  • 2The filing's primary purpose is to announce third-quarter financial results for the period ending September 30, 2003.
  • 3Financial results are disclosed through an attached press release (Exhibit 99.1).
  • 4The report is made pursuant to Regulation FD, ensuring broad dissemination of information.
  • 5Investors can find detailed financial performance data within the attached press release.
  • 6The filing covers 'Results of Operation and Financial Condition' under Item 12.
  • 7The filing was made by Edward M. Rodriguez, Vice President, Finance and Controller.

Frequently Asked Questions

The main purpose of this 8-K filing by IDEC Pharmaceuticals Corporation is to publicly announce and provide access to their financial results for the third quarter ended September 30, 2003, through an attached press release.

The detailed financial information, including the company's performance for the third quarter, is contained within the press release attached as Exhibit 99.1 to this Form 8-K.

This filing is required under Section 13 or 15(d) of the Securities Exchange Act of 1934 and adheres to Regulation FD, which mandates the disclosure of material non-public information to the public.

The filing date of October 14, 2003, indicates when the company officially reported its third-quarter financial results. The reported period is the three months ended September 30, 2003, providing investors with recent financial performance data.